[1]卡吾力·居买,居来提·艾尼瓦尔,张海平,等.食管癌精准治疗靶点筛查研究现状与展望[J].新乡医学院学报,2018,35(9):827-834.[doi:10.7683/xxyxyxb.2018.09.020]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(9):827-834.[doi:10.7683/xxyxyxb.2018.09.020]
点击复制

食管癌精准治疗靶点筛查研究现状与展望
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年9
页码:
827-834
栏目:
综述
出版日期:
2018-09-05

文章信息/Info

Title:
N/A
作者:
卡吾力·居买; 居来提·艾尼瓦尔; 张海平; 张力为; 伊力亚尔·夏合丁
（新疆医科大学第一附属医院胸外科，新疆维吾尔自治区食管癌研究所，新疆　乌鲁木齐　830011）
Author(s):
N/A
N/A
关键词:
食管癌; 精准医疗; 靶点筛查
Keywords:
N/A
分类号:
R735.1
DOI:
10.7683/xxyxyxb.2018.09.020
文献标志码:
A
摘要:
食管癌是世界上最为常见的消化系统恶性肿瘤之一，中国食管癌的发病率和病死率居世界第1位，约占全球食管癌的50%以上。食管癌恶性程度较高，且早期症状不典型，导致早期诊断困难，临床就诊患者多为中晚期，预后极差。随着食管外科手术技术的提高和放射治疗、化学治疗技术的不断创新，食管癌可切除率以及患者生存率有了一定提高，但顺铂、氟尿嘧啶等化学治疗药物毒副作用较大，很多患者无法耐受，且对化学治疗药物有耐药趋势，食管癌的5 a生存率仍不尽如人意。因此，不断有研究尝试食管癌生物靶向治疗及免疫治疗手段，探索相关分子作用的靶点，作为食管癌新的治疗方式靶标。本研究针对食管癌中已经开始研究的相关靶点、对应的靶向药物及其疗效、食管癌精准治疗靶点筛查趋势进行综述。
Abstract:
N/A

参考文献/References:

［1］　PARKIN D M，BARY F，FERLAY J，et al.Global cancer statistics，2012［J］.CA Cancer J Clin，2015，62（6）：102-110.
［2］　OHASHI S，MIYAMOTO S，KIKUCHI O，et al.Recent advances from basic and clinical studies of esophageal squamous cell carcinoma［J］.Gastroenterology，2015，149（7）：1700-1715.
［3］　SIEGEL R L，MILLER K D，JEMAL A.Cancer statistics，2015［J］.CA Cancer J Clin，2015，65（1）：5-29.
［4］　CHEN W Q，SUN K X，ZHEN R S g，et al.Cancer incidence and mortality in China，2014［J］.Chin J Cancer Res，2018，30（1）：1-12.
［5］　张雪娟，李寿玲，阿不都热合满·买买提，等.26 008例新发恶性肿瘤病例的流行病学特征分析［J］.中国病案，2016，17（9）：67-70.
［6］　AL MOUSTAFA A E，ACHKHAR A，YASMEEN A.EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas［J］.Front Biosci （Schol Ed），2012，4（2）：671-684.
［7］　CRONIN J，MCADAM E，DANIKAS A，et al.Epidermal growth factor receptor （EGFR） is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett′s esophagus （BE）［J］.Am J Gastroenterol，2011，106（1）：46-56.
［8］　IMAI K，TAKAOKA A.Comparing antibody and small-molecule therapies for cancer［J］.Nature Reviews Cancer，2006，6（9）：714-727.
［9］　HAN S W，OH D Y，IM S A，et al.Phase Ⅱ study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer［J］.Br J Cancer，2009，100（2）：298-304.
［10］　ENZINGER P C，BURTNESS B，HOLLIS D.CALGB 80403/ECOG 1206：a randomized phase Ⅱ study of three standard chemotherapy regimens （ECF，IC，FOLFOX） plus cetuximab in metastatic esophageal and GE junction cancer［J］.J Clin Oncol，2016，34（23）：2736.
［11］　LORDICK F，KANG Y K，CHUNG H C，et al.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer （EXPAND）：a randomised，open-label phase 3 trial［J］.Lancet Oncol，2013，14（6）：490-499.
［12］　WADDELL T，CHAU I，CUNNINGHAM D，et al.Epirubicin，oxaliplatin，and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer （REAL3）：a randomised，open-label phase 3 trial［J］.Lancet Oncol，2013，14（6）：481-489.
［13］　HAN X，LU N，PAN Y，et al.Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer［J］.Med Sci Monit，2017，23：412-418.
［14］　LIANG J，MINGYAN E，GANG W，et al.Nimotuzumab combined with radiotherapy for esophageal cancer：preliminary study of a Phase Ⅱ clinical trial［J］.Onco Targets Ther，2013，87（2）：1589-1596.
［15］　DE G C J，SEGALLA J G，DE S A，et al.A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer：NICE trial［J］.Eur J Cancer，2018，88：21-30.
［16］　JANMAAT M L，GALLEGOS-RUIZ M I，RODRIGUEZ J A，et al.Predictive factors for outcome in a phase Ⅱ study of gefitinib in second-line treatment of advanced esophageal cancer patients［J］.J Clin Oncol，2006，24：1612-1619.
［17］　RODRIGUEZ C P，ADELSTEIN D J，RICE T W，et al.A phase Ⅱ study of perioperative concurrent chemotherapy，gefitinib，and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer［J］.J Thorac Oncol，2010，5（2）：229-235.
［18］　ADELSTEIN D J，RYBICKI L A，IVES D I，et al.A phase Ⅱ trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction［J］.Invest New Drugs，2012，30（4）：1684-1689.
［19］　DRAGOVICH T，MCCOY S，FENOGLIO-PREISER C M，et al.Phase Ⅱ trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas：SWOG 0127［J］.J Clin Oncol，2006，24（30）：4922-4927.
［20］　WAINBERG Z A，LIN L S，DICARLO B，et al.Phase Ⅱ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction［J］.Br J Cancer，2011，105（6）：760.
［21］　LI G，HU W，WANG J，et al.Phase Ⅱ study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma［J］.Int J Radiat Oncol Biol Phys，2010，78（5）：1407-1412.
［22］　ZHANG Q，YU C，PENG S，et al.Autocrine VEGF signaling promotes proliferation of neoplastic Barrett′s epithelial cells through a PLC-dependent pathway［J］.Gastroenterology，2014，146（2）：461-472.
［23］　NIYAZ M，ANWER J，LIU H，et al.Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma［J］.Oncol Lett，2015，10（6）：3696.
［24］　FERRARA N，HILLAN K J，GERBER H P，et al.Discovery and development of bevacizumab，an anti-VEGF antibody for treating cancer［J］.Nat Rev Drug Discov，2004，3：391-400.
［25］　ELRAYES B F，ZALUPSKI M，BEKAISAAB T，et al.A phase Ⅱ study of bevacizumab，oxaliplatin，and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers［J］.Ann Oncol，2010，21（10）：1999.
［26］　SHAH M A，JHAWER M，ILSON D H，et al.Phase Ⅱ study of modified docetaxel，cisplatin，and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma［J］.J Clin Oncol，2011，29（7）：868-874.
［27］　KANG Y，OHTSU A，VAN C E，et al.AVAGAST：a randomized，double-blind，placebo-controlled，phase Ⅲ study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer （AGC）［J］.J Clin Oncol，2010，28（18_suppl）：LBA4007.
［28］　OKINES A F，REYNOLDS A R，CUNNINGHAM D.Targeting angiogenesis in esophagogastric adenocarcinoma［J］.Oncologist，2011，16（6）：844-858.
［29］　WILKE H，MURO K，VAN CUTSEM E，et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma （RAINBOW）：a double-blind，randomised phase 3 trial［J］.Lancet Oncol，2014，15（11）：1224-1235.
［30］　FUCHS C S，TOMASEK J，YONG C J，et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma （REGARD）：an international，randomised，multicentre，placebo-controlled，phase 3 trial［J］.Lancet，2014，383（9911）：31-39.
［31］　JAVLE M，SMYTH E C，CHAU I.Ramucirumab：successfully targeting angiogenesis in gastric cancer［J］.Clin Cancer Res，2014，20（23）：5875-5881.
［32］　GAN H K，SERUGA B，KNOX J J.Sunitinib in solid tumors［J］.Expert Opin Investig Drugs，2009，18（6）：821-834.
［33］　BANG Y J，KANG Y K，KANG W K，et al.Phase Ⅱ study of sunitinib as second-line treatment for advanced gastric cancer［J］.Invest New Drugs，2011，29（6）：1449-1458.
［34］　WU C，MIKHAIL S，WEI L，et al.A phase Ⅱ and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers［J］.Br J Cancer，2015，113（2）：220-225.
［35］　MOEHLER M，GEPFNERTUMA I，MADERER A，et al.Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus：a randomized，placebo-controlled phase Ⅱ AIO trial with serum biomarker program［J］.BMC Cancer，2016，16（1）：699.
［36］　ANASTASSIADIS T，DEACON S W，DEVARAJAN K，et al.Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity［J］.Nat Biotechnol，2011，29（11）：1039-1045.
［37］　SUN W，POWELL M，O′DWYER P J，et al.Phase Ⅱ study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma：ECOG 5203［J］.J Clin Oncol，2010，28（18）：2947.
［38］　JANJIGIAN Y Y，VAKIANI E，KU G Y，et al.Phase Ⅱ trial of sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal （GE） junction cancer［J］.PLoS One，2015，10（8）：e0134731.
［39］　LI J，QIN S，XU J，et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer：results from a randomized，placebo-controlled，parallel-arm，phase Ⅱ trial［J］.J Clin Oncol，2013，31（26）：3219.
［40］　LI J，QIN S，XU J，et al.Randomized，double-blind，placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］.J Clin Oncol，2016，34（13）：1448-1454.
［41］　SAMSON P，LOCKHART A C.Biologic therapy in esophageal and gastric malignancies：current therapies and future directions［J］.J Gastrointest Oncol，2017，8（3）：418-429.
［42］　LI J，WANG L.Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma［J］.Onco Targets Ther，2017，10：3965.
［43］　ROSS J S，MCKENNA B J.The HER-2/neu oncogene in tumors of the gastrointestinal tract［J］.Cancer Invest，2001，19（5）：554-568.
［44］　TAFE L J，JANJIGIAN Y Y，ZAIDINSKI M，et al.Human epidermal growth factor receptor 2 testing in gastroesophageal cancer：correlation between immunohistochemistry and fluorescence in situ hybridization［J］.Arch Pathol Lab Med，2011，135（11）：1460-1465.
［45］　BANG Y J，VAN C E，FEYEREISLOVA A，et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer （ToGA）：a phase 3，open-label，randomised controlled trial［J］.J Digest Oncol，2010，376（9742）：687-697.
［46］　ROSSI E，GRISANTI S，VILLANACCI V，et al.HER-2 overexpression/amplification in Barrett′s oesophagus predicts early transition from dysplasia to adenocarcinoma：a clinico-pathologic study［J］.J Cell Mol Med，2010，13（9b）：3826-3833.
［47］　SAWAKI A，OHASHI Y，OMURO Y，et al.Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer：a subgroup analysis of the Trastuzumab for Gastric Cancer （ToGA） study［J］.Gastric Cancer，2012，15（3）：313-322.
［48］　RADIATION THERAPY ONCOLOGY GROUP.RTOG 1010：a phase Ⅲ trial evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma［EB/OL］.［2015-11-10］［2018-03-01］.https：//www.nrgoncology.org/Clinical-Trials/Protocol-Table.
［49］　FRANKLIN M C，CAREY K D，VAJDOS F F，et al.Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex［J］.Cancer Cell，2004，5（4）：317-328.
［50］　KANG Y K，RHA S Y，TASSONE P，et al.A phase Ⅱa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab，capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer［J］.Br J Cancer，2014，111（4）：660-666.
［51］　HOFFMANN-LA ROCHE.A study of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction or gastric cancer［EB/OL］.［2013-01-23］［2018-03-01］.http：//clinicaltrials.gov/ct2/show/NCTO1774786.
［52］　THUSS-PATIENCE P C，SHAH M A，OHTSU A，et al.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma （GATSBY）：an international randomised，open-label，adaptive，phase 2/3 study［J］.Lancet Oncol，2017，18（5）：640-653.
［53］　GUO X F，ZHU X F，ZHONG G S，et al.Lapatinib，a dual inhibitor of egfr and her2，has synergistic effects with 5-fluorouracil on esophageal carcinoma［J］.Oncol Rep，2012，27：1639-1645.
［54］　SATOH T，XU R H，CHUNG H C，et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations：TyTAN-a randomized，phase Ⅲ study［J］.J Clin Oncol，2015，32（19）：2039-2049.
［55］　HECHT J R，BANG Y J，QIN S K，et al.Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric，esophageal，or gastroesophageal adenocarcinoma：TRIO-013/LOGiC-a randomized phase Ⅲ trial［J］.J Clin Oncol，2015，34（5）：443-451.
［56］　SHEPARD G，ARROWSMITH E R，MURPHY P，et al.A Phase Ⅱ study with lead-in safety cohort of 5-fluorouracil，oxaliplatin，and lapatinib in combination with radiation therapy as neoadjuvant treatment for patients with localized HER2-positive esophagogastric adenocarcinomas［J］.Oncologist，2017，22（10）：1152-1198.
［57］　CHI H W，MA B B Y，HUI C W C，et al.Preclinical evaluation of afatinib （BIBW2992） in esophageal squamous cell carcinoma （ESCC）［J］.Am J Cancer Res，2015，5（12）：3588-3599.
［58］　JANJIGIAN Y Y，IMTIAZ T，ILSON D H，et al.Abstract CT228：a phase Ⅱ study of afatinib （A） in patients （pts） with metastatic human epidermal growth factor receptor （HER2）-positive trastuzumab （T） refractory esophagogastric （EG） cancer［J］.Cancer Res，2014，74（19）：CT228-CT228.
［59］　HIRASHIMA K，BABA Y，WATANABE M，et al.Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma［J］.Ann Surg Oncol，2010，17（9）：2486-2493.
［60］　HIRASHIMA K，BABA Y，WATANABE M，et al.Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma［J］.Br J Cancer，2012，106（5）：876-882.
［61］　DOI T，MURO K N，YAMADA Y，et al.Multicenter phase Ⅱ study of everolimus in patients with previously treated metastatic gastric cancer［J］.J Clin Oncol，2010，28（11）：1904-1910.
［62］　OHTSU A，AJANI J A，BAI Y X，et al.Everolimus for previously treated advanced gastric cancer：results of the randomized，double-blind，phase Ⅲ GRANITE-1 study［J］.J Clin Oncol，2013，31（31）：3935.
［63］　HACK S P，BRUEY J M，KOEPPEN H.HGF/MET-directed therapeutics in gastroesophageal cancer：a review of clinical and biomarker development［J］.Oncotarget，2014，5（10）：2866-2880.
［64］　SMYTH E C，SCLAFANI F，CUNNINGHAM D.Emerging molecular targets in oncology：clinical potential of MET/hepatocyte growth-factor inhibitors［J］.Onco Targets Ther，2014，6（7）：1001-1014.
［65］　CATENACCI D，TEBBUTT N C，DAVIDENKO I，et al.Rilotumumab plus epirubicin，cisplatin，and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer （RILOMET-1）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］.Lancet Oncol，2017，18（11）：1467-1482.
［66］　DOI T，YAMAGUCHI K，KOMATSU Y，et al.A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer［J］.Jpn J Clin Oncol，2017，47（11）：1002-1009.
［67］　CATENACCI D V T，HENDERSON L，XIAO S Y，et al.Durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence［J］.Cancer Discov，2011，1（7）：573-579.
［68］　SHAH M A，CHO J Y，HUAT I T B，et al.Randomized phase Ⅱ study of FOLFOX+/-MET inhibitor，onartuzumab （O），in advanced gastroesophageal adenocarcinoma （GEC）［J］.J Clinic Oncol，2015，33（3）：2.
［69］　SHAH M A，BANG Y J，LORDICK F，et al.METGastric：a phase Ⅲ study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative （HER2-） and MET-positive （MET+） adenocarcinoma of the stomach or gastroesophageal junction （GEC）［J］.J Clinic Oncol，2015，33（4）：60.
［70］　LENNERZ J K，KWAK E L，ACKERMAN A，et al.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib［J］.J Clinic Oncol，2011，29（36）：4803-4810.
［71］　YANG Y，WU N，SHEN J，et al.MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer［J］.Gastric Cancer，2016，19（3）：778-788.
［72］　KANG Y K，MURO K，RYU M H，et al.A phase Ⅱ trial of a selective c-Met inhibitor tivantinib （ARQ 197） monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer［J］.Invest New Drugs，2014，32（2）：355-361.
［73］　SHAH M A，WAINBERG Z A，CATENACCI D V，et al.Phase Ⅱ study evaluating 2 dosing schedules of oral foretinib （GSK1363089），cMET/VEGFR2 inhibitor，in patients with metastatic gastric cancer［J］.PLoS One，2013，8（3）：e54014.
［74］　KWAK E L，LORUSSO P，HAMID O，et al.Clinical activity of AMG 337，an oral MET kinase inhibitor，in adult patients （pts） with MET-amplified gastroesophageal junction （GEJ），gastric （G），or esophageal （E） cancer［J］.J Clinic Oncol，2015，33（3）：1.

相似文献/References:

[1]原志庆,王凤荣,吴国祥,等.食管癌切除标本断端残留癌的流式细胞分析[J].新乡医学院学报,1991,8(01):012.
[2]彭明轩,张一峰.食管癌与贲门癌238例手术治疗及其并发症分析[J].新乡医学院学报,1992,9(01):048.
[3]刘玉梅,申维玺,姚卫华,等.氟尿嘧啶合并醛氢叶酸治疗食管癌疗效评价[J].新乡医学院学报,1995,12(02):123.
[4]原志庆,许春雷.瘤体内DNA倍体异质性与食管鳞状细胞癌病理特性的关系[J].新乡医学院学报,1995,12(01):005.
[5]常银江,马森林,王守义,等.上段食管癌切除后食管床内胃食管颈部吻合术[J].新乡医学院学报,1996,13(02):143.
[6]王俊英,李国群,董长宪,等.食管癌合并糖尿病患者的围手术期处理[J].新乡医学院学报,1996,13(02):151.
[7]陈国荣.中晚期食管癌夹心治疗近期疗效分析 [J].新乡医学院学报,1997,14(02):150.
[8]李慧清,李汉臣,杨红伟,等.不同食管胃吻合方法术后生活质量分析[J].新乡医学院学报,1997,14(03):213.
[9]郭玉军,吴阶清,刘新秋,等.双介入疗法治疗晚期食管癌[J].新乡医学院学报,1997,14(03):287.
[10]乔　刚　李汉臣　席红军　王忠民　崔　玉　韩培立　赵宝生.食管癌患者手术前后细胞免疫的变化[J].新乡医学院学报,1999,16(04):308.

更新日期/Last Update: 2018-09-05